Publication
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.
Authors not recorded
J Clin Invest2019PMID 30835257PMC6486352stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMelanomacivic_curation1.00
- drugCobimetinibcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneRAF1civic_curation1.00
- variantRAF1 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30835257
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RAF1 Fusion1 | ||||||||
| Cobimetinib + TrametinibSubstitutes | Melanoma | Predictive | C | Supports Sensitivity Response | 5 | accepted | EID8374In a case study of a metastatic melanoma with a GOLGA4-RAF1 fusion, the patient was administered MEK inhibitor therapy in the absence of other actionable variants. This resulted in a profound and clin… (full text at CIViC) PMID 30835257 · McEvoy et al., 2019 · Open in CIViC | civic |